Business context and reporting period
Geron Corporation’s Form 10-K covers the fiscal year ended December 31, 2015. Geron is a clinical-stage biopharmaceutical company whose sole drug candidate, imetelstat, is exclusively licensed worldwide to Janssen for development and commercialization. Janssen runs the program; Geron shares 50% of the costs of the IMbark myelofibrosis and IMerge myelodysplastic syndromes trials.
Financial performance and position
Amounts are in U.S. dollars; financial statement figures are in millions unless noted.
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $36.37 | $1.15 |
| Operating expenses | $36.93 | $37.47 |
| Operating income (loss) | $(0.56) | $(36.31) |
| Net income (loss) | $0.046 | $(35.67) |
| Net income (loss) per share, diluted | $0.00 | $(0.23) |
| Research and development expense | $17.83 | $20.71 |
| General and administrative expense | $17.79 | $16.76 |
| Net cash from (used in) operating activities | $(24.20) | $9.35 |
| Cash, restricted cash, cash equivalents and marketable securities | $146.70 | $170.64 |
| Working capital | $109.26 | $111.61 |
2015 revenue included the full recognition of Janssen’s $35 million upfront payment in the third quarter, following completion of license delivery and technology transfer. It represented approximately 96% of annual revenue. License fees and royalties were $1.37 million. The resulting 0.1% net margin and $46,000 profit do not reflect recurring product sales; Geron reported an operating loss.
At year-end, current assets were $115.89 million and current liabilities $6.63 million. The filing reports no debt balance; it lists $1.73 million of contractual cash obligations, principally operating lease commitments. The accumulated deficit was $928.39 million. Geron’s 2015 cash flows included $2.58 million from financing activities; 2014 financing included $96.81 million net proceeds from a public offering. No material interest-rate exposure was identified by management.
Material changes versus the prior comparable period
- Revenue rose sharply because the deferred Janssen upfront payment was recognized in 2015; without it, the company remained loss-making operationally.
- Net income improved from a $35.67 million loss to $46,000, while operating expenses declined by $0.54 million. R&D fell 14%, primarily reflecting lower personnel and manufacturing costs, partly offset by higher collaborative trial costs.
- Operating cash flow shifted from $9.35 million provided in 2014 to $24.20 million used in 2015. The 2014 inflow reflected receipt of the Janssen upfront payment in December 2014, while cash and investments declined $23.94 million during 2015.
- Geron completed a workforce resizing, reducing positions from 39 to 21; year-end staffing was 17 full-time and three part-time employees. 2015 restructuring charges were $1.31 million.
Outlook, commentary, risks and unusual items
- Management estimated existing capital resources and future interest income would fund the current level of operations for at least 12 months from the filing’s date, while expecting negative cash flow and continued operating losses. Geron cautioned that resources could be used sooner than anticipated.
- For 2016, management expected direct external R&D costs to increase as imetelstat development progresses, partly offset by lower personnel costs; G&A was expected to remain consistent. Janssen’s IMbark data cut was expected in the second half of 2017, subject to enrollment and other factors. Janssen planned an internal review of IMbark and IMerge data in the second half of 2016.
- Under the collaboration, potential future payments include up to $900 million in milestones plus royalties, but none are assured. Following an affirmative continuation decision, Geron’s U.S. opt-in election would involve sharing 20% of further U.S. development and promotion costs for higher potential milestone and royalty tiers; otherwise, Janssen bears those later costs and Geron’s potential royalty tier is lower.
- Key risks include dependence on Janssen and its continuation decision; uncertain clinical efficacy and regulatory approval; liver-function abnormalities and potentially severe cytopenias, including a treatment-associated death reported in the MF pilot study; manufacturing and supply dependence; competition; financing needs; and patent risks.
- Several securities and derivative lawsuits related to disclosures about imetelstat liver-test abnormalities remained pending; some claims survived a motion to dismiss, derivative cases were stayed, and potential liability could not be estimated. The company had not recorded a reserve for these matters.
- Auditors issued unqualified opinions on the financial statements and internal control over financial reporting. Management reported effective disclosure controls and internal controls as of December 31, 2015.
Important facts for investors to verify
- Whether Janssen’s clinical trial data, safety findings, enrollment progress and continuation decision support further development of imetelstat.
- How much of reported earnings and revenue reflects the one-time $35 million upfront payment, and the company’s cash burn after that recognition.
- Whether the stated 12-month funding estimate remains adequate given trial cost-sharing, any opt-in decision, acquisitions and other planned expenditures.
- The status and potential financial impact of the securities and derivative litigation, for which the filing provides no clear loss estimate.
- Whether clinical, manufacturing, regulatory or financing developments alter Geron’s reliance on Janssen or require additional capital, potentially diluting shareholders.